Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Illustration: Rebecca Zisser/Axios
Moderna Therapeutics, a Massachusetts startup that wants to revolutionize drug manufacturing, on Friday filed for what could be the largest-ever IPO for a biotech startup.
The bottom line: Moderna creates synthetic mRNA, which is injected into patients so they can create their own therapies. It's an entirely new way to think about making medicine, and it also could lend itself to a modular approach whereby it doesn't need different facilities for different products.
- Moderna filed to raise $500 million and reports a $243 million net loss on around $100 million in revenue for the first nine months of 2018.
- It plans to trade on the Nasdaq under ticker symbol MRNA.
- Morgan Stanley is lead underwriter, but 10 other investment banks are also listed.
The company has raised nearly $2 billion in venture capital funding, most recently at a $7.5 billion valuation.
- Shareholders include Flagship Pioneering, AstraZeneca, Abu Dhabi Investment Authority, BB Biotech, Julius Baer, EDBI, Sequoia Capital China, Fidelity, Pictet, Viking Global Investors, ArrowMark Partners and Alexandria Venture Investments.
Its goal is to be involved in treatments for infectious diseases, immuno-oncology and rare diseases.